Fig. 3.

Protein–ligand interaction for the SARS-CoV-2 NSP13 and NSP16. A Protein–ligand interaction of the SARS-CoV-2 NSP13 and ivermectin after completion of docking operation in Autodock Vina. The interaction in the docked complex was visualized using Discovery Studio. B Protein–ligand interaction of the SARS-CoV-2 NSP13 and scutellarein after completion of docking operation in Autodock Vina. C Protein–ligand interaction of the SARS-CoV-2 NSP16 and hamamelitannin after completion of docking operation in Autodock Vina. The interaction in the docked complex was visualized using Discovery Studio. D Protein–ligand interaction of the SARS-CoV-2 NSP16 and deacyltunicamycin after completion of docking operation in Autodock Vina. The interaction in the docked complex was visualized using Discovery Studio